Featured Research Search Results
Featured research search results for
Helping Latinas Understand Their Risk for Breast Cancer and Get Breast Cancer Care
Clinicaltrials.gov identifier:
NCT05483283
Prevention
Latinas with a high risk of breast cancer
Upright MRI for Prostate Cancer Screening
Clinicaltrials.gov identifier:
NCT03474913
Prevention
Screening for prostate cancer using upright MRI
Bazedoxifene Plus Conjugated Estrogens for Hot Flashes in Women at High Risk for Breast Cancer
Clinicaltrials.gov identifier:
NCT04821141
Quality of Life
Women at high risk for breast cancer due to ATM, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11, P53 or PTEN mutation who have hot flashes
BRCA 1 and BRCA 2: Interviews on Genetic Testing and Individual Experiences
Surveys, Registries, Interviews
People with or without cancer who have had or are considering BRCA testing
Cancer Experience Registry
Surveys, Registries, Interviews
Online survey for patients and caregivers focusing on multiple aspects of cancer
SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells
Clinicaltrials.gov identifier:
NCT04150042
Treatment
Advanced pancreatic cancer or stage 4 breast cancer in people with a BRCA1 or BRCA2 mutation
All of Us Research Program
Surveys, Registries, Interviews
Anyone age 18 or over can participate in this research study
Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)
Clinicaltrials.gov identifier:
NCT04644068
Treatment
Advanced ovarian, breast, prostate or pancreatic cancer
Inherited Cancer Registry (ICARE): Contribute to Research While Staying Informed
Clinicaltrials.gov identifier:
NCT03231891
Surveys, Registries, Interviews
Registry for with an inherited mutation or cancer in the family
Adding Pembrolizumab to Olaparib to Treat Pancreatic Cancer in People with an Inherited BRCA Mutation
Clinicaltrials.gov identifier:
NCT04548752
Treatment
Metastatic pancreatic cancer and a BRCA1 or BRCA2 mutation
Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors
Clinicaltrials.gov identifier:
NCT04657068
Treatment
Advanced solid tumors
Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-L1 Inhibitor
Clinicaltrials.gov identifier:
NCT03607890
Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
Clinicaltrials.gov identifier:
NCT04042831
Treatment
Treatment study for people with metastatic biliary tract (bile duct) cancer and who have an inherited or tumor mutation
Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families
Prevention
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation
Blood Tests to Measure Ovarian Reserves in Women with a BRCA Mutation or Women Treated for Early-Stage Breast Cancer
Clinicaltrials.gov identifier:
NCT00823654
Prevention
Study for premenopausal women with early-stage breast cancer and high-risk women with BRCA mutations and no evidence of breast or ovarian cancer
Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations
Clinicaltrials.gov identifier:
NCT03990896
Treatment
Treatment study for people with metastatic breast cancer without a known mutation in BRCA1 or BRCA2, who learn they have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation)
Pancreatic Cancer Screening Study for High Risk People
Clinicaltrials.gov identifier:
NCT03250078
Prevention
Screening study to detect pancreatic cancer and precancer
Connect My Variant
Surveys, Registries, Interviews
Study for people with an inherited mutation to help them talk with relatives about their family history and genetic test results, connect them to others with the same variant and to their family trees